Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Gilead Sciences has outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

Investors in Gilead Sciences, Inc. GILD need to pay close attention to the stock based on moves in the options market lately. That is because the Feb. 20, 2026 $150.00 Put had some of the highest ...

Sana Biotechnology's favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a sizeable TAM in TD1. Learn more about SANA stock here.

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms ...

Gilead Sciences Inc. stock reached an all-time high of 128.71 USD, marking a significant milestone for the biopharmaceutical company. According to InvestingPro data, the stock is trading just 0.99% ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...